• Je něco špatně v tomto záznamu ?

Mutational landscape of plasma cell-free DNA identifies molecular features associated with therapeutic response in patients with colon cancer. A pilot study

K. Cervena, B. Pardini, M. Urbanova, S. Vodenkova, P. Eva, V. Veskrnova, M. Levy, T. Buchler, M. Mokrejs, A. Naccarati, P. Vodicka, V. Vymetalkova

. 2021 ; 36 (5) : 358-368. [pub] 20211006

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22008385

Grantová podpora
NV17-30920A MZ0 CEP - Centrální evidence projektů

Cell-free DNA (cfDNA) has recently been used as a non-invasive diagnostic tool for detecting tumour-specific mutations. cfDNA may also be used for monitoring disease progression and treatment response, but so far researchers focused on one or few genes only. A genomic profile may provide better information on patient prognosis compared to single specific mutations. In this hypothesis-generating study, we profiled by whole exome sequencing serial plasma samples from 10 colon cancer (CC) patients collected before and after 5-fluorouracil-based therapy, and one year after diagnosis to determine alterations associated with treatment response. In parallel, genome profiling was also performed in patients' corresponding tumour tissue to ascertain the molecular landscape of resistant tumours. The mutation concordance between cfDNA and tumour tissue DNA was higher in more advanced tumour stages than in the early stages of the disease. In non-responders, a specific mutation profile was observed in tumour tissues (TPSD1 p.Ala92Thr, CPAMD8 p.Arg341Gln, OBP2A p.ArgTyr123CysHis). A pathogenic APC mutation (p.Ser1315Ter) was detected only in cfDNA of one poor responder one year after the diagnosis and after therapy termination. Another poor responder presented a likely pathogenic TP53 mutation (p.Arg110Pro) in cfDNA of all plasma samplings and in tumour tissue. In conclusion, cfDNA could be used for genetic characterisation of CC patients and might be clinically useful for non-invasive therapy response monitoring.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22008385
003      
CZ-PrNML
005      
20220321103057.0
007      
ta
008      
220321s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/mutage/geab024 $2 doi
035    __
$a (PubMed)34214148
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Cervena, Klara $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000209480130
245    10
$a Mutational landscape of plasma cell-free DNA identifies molecular features associated with therapeutic response in patients with colon cancer. A pilot study / $c K. Cervena, B. Pardini, M. Urbanova, S. Vodenkova, P. Eva, V. Veskrnova, M. Levy, T. Buchler, M. Mokrejs, A. Naccarati, P. Vodicka, V. Vymetalkova
520    9_
$a Cell-free DNA (cfDNA) has recently been used as a non-invasive diagnostic tool for detecting tumour-specific mutations. cfDNA may also be used for monitoring disease progression and treatment response, but so far researchers focused on one or few genes only. A genomic profile may provide better information on patient prognosis compared to single specific mutations. In this hypothesis-generating study, we profiled by whole exome sequencing serial plasma samples from 10 colon cancer (CC) patients collected before and after 5-fluorouracil-based therapy, and one year after diagnosis to determine alterations associated with treatment response. In parallel, genome profiling was also performed in patients' corresponding tumour tissue to ascertain the molecular landscape of resistant tumours. The mutation concordance between cfDNA and tumour tissue DNA was higher in more advanced tumour stages than in the early stages of the disease. In non-responders, a specific mutation profile was observed in tumour tissues (TPSD1 p.Ala92Thr, CPAMD8 p.Arg341Gln, OBP2A p.ArgTyr123CysHis). A pathogenic APC mutation (p.Ser1315Ter) was detected only in cfDNA of one poor responder one year after the diagnosis and after therapy termination. Another poor responder presented a likely pathogenic TP53 mutation (p.Arg110Pro) in cfDNA of all plasma samplings and in tumour tissue. In conclusion, cfDNA could be used for genetic characterisation of CC patients and might be clinically useful for non-invasive therapy response monitoring.
650    _2
$a senioři $7 D000368
650    12
$a nádorové biomarkery $7 D014408
650    12
$a volné cirkulující nukleové kyseliny $7 D000073888
650    _2
$a nádory tračníku $x krev $x diagnóza $x genetika $x terapie $7 D003110
650    12
$a DNA nádorová $7 D004273
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $x farmakologie $7 D005472
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a sekvenční analýza DNA $7 D017422
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pardini, Barbara $u IIGM Italian Institute for Genomic Medicine, Sp142 Km3.95, 100 60 Candiolo, Turin, Italy $u Candiolo Cancer Institute, FPO-IRCCS, Sp142 Km3.95, 100 60 Candiolo, Turin, Italy
700    1_
$a Urbanová, Markéta $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic $7 _AN103160
700    1_
$a Vodenkova, Sona $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00 Pilsen, Czech Republic
700    1_
$a Pazourková, Eva $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic $u Department of Nephrology, First Faculty of Medicine, Charles University and General Faculty Hospital in Prague, U nemocnice 2, 121 08 Prague, Czech Republic $7 xx0208969
700    1_
$a Veskrnova, Veronika $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic
700    1_
$a Levý, Miroslav $u Department of Surgery, Thomayer University Hospital, Videnska 800, 140 59 Prague, Czech Republic $7 xx0198664
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic
700    1_
$a Mokrejs, Martin $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00 Pilsen, Czech Republic
700    1_
$a Naccarati, Alessio $u IIGM Italian Institute for Genomic Medicine, Sp142 Km3.95, 100 60 Candiolo, Turin, Italy $u Candiolo Cancer Institute, FPO-IRCCS, Sp142 Km3.95, 100 60 Candiolo, Turin, Italy $1 https://orcid.org/0000000157740905 $7 xx0118173
700    1_
$a Vodička, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00 Pilsen, Czech Republic $7 xx0060269
700    1_
$a Vymetálková, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00 Pilsen, Czech Republic $1 https://orcid.org/0000000168706788 $7 xx0102721
773    0_
$w MED00003429 $t Mutagenesis $x 1464-3804 $g Roč. 36, č. 5 (2021), s. 358-368
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34214148 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220321 $b ABA008
991    __
$a 20220321103054 $b ABA008
999    __
$a ok $b bmc $g 1772149 $s 1159579
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 36 $c 5 $d 358-368 $e 20211006 $i 1464-3804 $m Mutagenesis $n Mutagenesis $x MED00003429
GRA    __
$a NV17-30920A $p MZ0
LZP    __
$a 2021-granty

Najít záznam

Citační ukazatele

Možnosti archivace